In a pre-print study with The Lancet, the research team – from Oxford, Nanoro in Burkina Faso and the US – reported the trial results of R21/Matrix-M, after testing a low and high dose of the vaccine in children, between May and August, before peak malaria season.
Click Here to Visit Orignal Source of Article https://www.bbc.co.uk/news/health-56858158
